Update on neuropathies associated with monoclonal gammopathy of undetermined significance (2008-2010)

Research output: Contribution to journalArticlepeer-review

Abstract

Studies on paraproteinemic neuropathies have appeared in the last 2 years improving the diagnosis of these neuropathies, clarifying their pathogenesis, and informing practice by randomized clinical trial publications. Two recent randomized controlled trials with rituximab failed to provide evidence of efficacy in primary outcome measures, despite the fact that anti-myelin- associated glycoprotein (MAG) antibodies were reduced in most treated patients. This discrepancy, besides inducing the search for more effective therapy for this neuropathy, indicates that some aspects on the pathogenesis of this neuropathy probably need further clarification.

Original languageEnglish
Pages (from-to)302-306
Number of pages5
JournalJournal of the Peripheral Nervous System
Volume15
Issue number4
DOIs
Publication statusPublished - Dec 2010

Keywords

  • antibodies
  • ganglioside complexes
  • GQ1b
  • IgM
  • MAG
  • monoclonal gammopathy
  • neuropathy
  • rituximab
  • sulfatide

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Update on neuropathies associated with monoclonal gammopathy of undetermined significance (2008-2010)'. Together they form a unique fingerprint.

Cite this